Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Biotechnology

Healthcare
$37.75 -0.55%

-$0.29 today

Market cap
$3.71B
Beta
0.63
P/E (TTM)
-12.1
EPS (TTM)
-$4.39
52W Low $30.00High $63.95

Volume 1.30M

Average 1.16M

XENE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Xenon Pharmaceuticals Inc.NASDAQ: XENE

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 99.77M shares rose 25.9% year over year, ahead of the +16.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.9% holds above the trailing-twelve-month pace of +16.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
99.77M+0.2% QoQ
Last fiscal yearDec 2025
79.25M+1.7% YoY
LTMSep 2026
91.49M+16.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.9%——
1 year+1.7%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
79.25M USD
Year-over-year change
+1.7%
4-year CAGR
+16.1%

Weighted Avg Shares vs competitors

How XENE compares with its peers on the latest reported figures

  • XENE's LTM Sep 2026 weighted avg shares of 91.49M shares is the 5th highest of the 11 companies compared; the peer median is 74.52M shares.
  • Its year-over-year change of +16.1% is the 3rd highest of 11, against a peer median of +3.6%.
  • Over three fiscal years its annual growth of +9.4% compares with a peer median of +3.0%.
XENE Competitors Peer median
Weighted Avg Shares for XENE and competitors
Company Period LTM YoY 3-year CAGR
DNLIDenali Therapeutics Inc.LTM Jun 2026180.46M +5.8%+11.8%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026171M +2.1%+1.6%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026100.65M +1.1%+1.3%
XENEXenon Pharmaceuticals Inc.LTM Sep 202691.49M +16.1%+9.4%
AVXLAnavex Life Sciences Corp.LTM Dec 202586.34M +2.9%+3.5%
JAZZJazz Pharmaceuticals plcLTM Sep 202662.7M +3.0%-0.8%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202657.36M +3.1%+1.7%
AXSMAxsome Therapeutics, Inc.LTM Jun 202650.84M +4.3%+7.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
PRAXPraxis Precision Medicines, Inc.LTM Sep 202627.42M +29.8%+94.2%
Peer median (excluding XENE) 74.52M+3.6%+3.0%

Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.44M9.43M007.5M
Cost of Revenue00167.51M2.56M2.54M
Gross Profit18.44M9.43M(167.51M)(2.56M)4.96M
Gross Margin100.0%100.0%——66.1%
Research & Development75.46M105.77M167.51M210.39M300.94M
Selling, General & Admin21.97M32.81M46.54M68.9M79.63M
Operating Expenses97.43M138.58M46.54M276.74M378.03M
Depreciation & Amortization906K1.41M3.54M2.56M2.54M
EBITDA(78.09M)(127.74M)(210.51M)(235.86M)(342.35M)
EBITDA Margin-423.5%-1354.0%——-4564.7%
Operating Income(78.99M)(129.14M)(214.05M)(279.3M)(373.07M)
Operating Margin-428.4%-1368.9%——-4974.3%
Interest Income466K8.71M27.62M41.94M26.83M
Interest Expense00000
Other Income / Expenses105K3.89M31.37M40.88M28.18M
Income Before Tax(78.89M)(125.26M)(182.69M)(238.42M)(344.89M)
Pre-Tax Margin-427.9%-1327.7%——-4598.6%
Income Tax Expense(6K)118K(292K)(4.09M)1.02M
Net Income(78.88M)(125.37M)(182.39M)(234.33M)(345.91M)
Net Margin-427.8%-1328.9%——-4612.1%
EPS (Basic)(1.77)(2.06)(2.73)(3.01)(4.36)
EPS (Diluted)(1.77)(2.06)(2.73)(3.01)(4.36)
Weighted Avg Shares43.63M60.54M66.89M77.89M79.25M
Weighted Avg Shares (Diluted)43.63M60.54M66.89M77.89M79.25M

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Intrinsic Alpha fair value

Locked

Current Price

$37.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.